ArticleGenes & development2014
Active enhancers are delineated de novo during hematopoiesis, with limited lineage fidelity among specified primary blood cells.
Article in Genes & development, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Aged differentiated cells reverse into native stemness-like state by niche cytokines to sustain lifelong homeostasis and tissue repair.Nature communications · 2026Article
- Enhancer Trajectories in Lineage Commitment: Regulatory Logic of States and Cooperation.Biomolecules · 2026Review
- In vivo transition in chromatin accessibility during differentiation of deep-layer excitatory neurons in the neocortex.Development (Cambridge, England) · 2025Article
- Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation.Nature genetics · 2025Article
- Developmental cues license megakaryocyte priming in murine hematopoietic stem cells.Blood advances · 2022Article
- Paligenosis: Cellular Remodeling During Tissue Repair.Annual review of physiology · 2022Review
- Epigenetic Analysis of the Chromatin Landscape Identifies a Repertoire of Murine Eosinophil-Specific PU.1-Bound Enhancers.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Deregulation of Transcriptional Enhancers in Cancer.Cancers · 2021Review
- Differential usage of transcriptional repressor Zeb2 enhancers distinguishes adult and embryonic hematopoiesis.Immunity · 2021Article
- Transcriptional regulatory network controlling the ontogeny of hematopoietic stem cells.Genes & development · 2020Article
- Enhancers and MYC interplay in hematopoiesis.Journal of molecular medicine (Berlin, Germany) · 2020Review
- Article
- Nickel-induced transcriptional changes persist post exposure through epigenetic reprogramming.Epigenetics & chromatin · 2019Article
- A Unique Epigenomic Landscape Defines Human Erythropoiesis.Cell reports · 2019Article
- Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.Cellular and molecular life sciences : CMLS · 2018Review
- Lineage specific transcription factors and epigenetic regulators mediate TGFβ-dependent enhancer activation.Nucleic acids research · 2018Article
- A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.Molecular cell · 2017Article
- Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.Current opinion in hematology · 2017Review
- Article
- NF-E2, FLI1 and RUNX1 collaborate at areas of dynamic chromatin to activate transcription in mature mouse megakaryocytes.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Tissues may adopt diverse strategies to establish specific transcriptional programs in daughter lineages. In intestinal crypts, enhancers for genes expressed in both major cell types appear broadly permissive in stem and specified progenitor cells. In blood, another self-renewing tissue, it is unclear when chromatin becomes permissive for transcription of genes expressed in distinct terminal lineages. Using chromatin immunoprecipitation (ChIP) combined with deep sequencing (ChIP-seq) to profile activating histone marks, we studied enhancer dynamics in primary mouse blood stem, progenitor, and specified cells. Stem and multipotent progenitor cells show scant H3K4me2 marking at enhancers bound by specific transcription factors in their committed progeny. Rather, enhancers are modulated dynamically and serially, with substantial loss and gain of H3K4me2, at each cellular transition. Quantitative analysis of these dynamics accurately modeled hematopoiesis according to Waddington's notion of epigenotypes. Delineation of enhancers in terminal blood lineages coincides with cell specification, and enhancers active in single lineages show well-positioned H3K4me2- and H3K27ac-marked nucleosomes and DNaseI hypersensitivity in other cell types, revealing limited lineage fidelity. These findings demonstrate that enhancer chronology in blood cells differs markedly from that in intestinal crypts. Chromatin dynamics in hematopoiesis provide a useful foundation to consider classical observations such as cellular reprogramming and multilineage locus priming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.